Chimeric Therapeutics Ltd has released a press release.
Clinical milestones for 2024 & 2023 successes highlighted
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Half Yearly Report and Accounts
- 1st patient treated in ADVENT-AML Phase 1b clinical trial
- Placement of Entitlement Offer Shortfall
- ADVENT-AML Phase 1B clinical trial open to enrolment
- Chimeric receives $7.36M R&D tax incentive
Later from Chimeric Therapeutics
- Resignation of CEO and Managing Director
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Chimeric opens CHM CDH17 Phase 1/2 trial
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics